RLN2 and cardiovascular disorder: The promising use of relaxin-2 as a biomarker, risk predictor or therapeutic agent in cardiovascular disease is based on its probed capacity as a suppressor of inflammation and fibrosis, two physiopathological mechanisms of great relevance in AF and heart failure (HF)19,20.